Compare First Solar, Inc. (FSLR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? First Solar, Inc. trades at $216.72 (market cap $24.05B), while Regeneron Pharmaceuticals Inc trades at $672.83 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.9× First Solar, Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals.
| FSLR | REGN | |
|---|---|---|
Market Cap | $24.05B | $69.66B |
Sector | Technology | Health |
52-Week High | $318.30 | $812.27 |
52-Week Low | $166.82 | $542.52 |
Enterprise Value | $22.21B | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $220.58, down 0.2% on the day, with a bearish technical signal driven by moving averages. The company shows strong fundamentals with a P/E of 14.46, net income margin of 30.73%, and robust cash flow from operations of $2.06B in 2025. Recent earnings beat in Q1 2026 but missed in prior quarters. Multiple class-action lawsuits filed in July 2026 allege securities fraud, creating near-term legal overhang.
The stock presents a mixed outlook: solid profitability and analyst consensus price target of $275.17 suggest upside, but legal risks and bearish technicals weigh. Investors face tension between strong financial health and potential volatility from litigation outcomes.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
